Moleculin Biotech Inc (MBRX)

02:02 AM

Moleculin Biotech Inc. Stock Analysis and ForecastExponential wealth increase - jammulinksnews.com

02:02 AM

Jul 22, 2025

Is Moleculin Biotech Inc. a good long term investmentConsistent triple-digit returns - jammulinksnews.com

Jul 22, 2025

Jul 22, 2025

Moleculin Participates in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference - GlobeNewswire

Jul 22, 2025

Jul 22, 2025

Moleculin Participates in the Virtual Investor 'What’s Your Story” Summer Spotlight On-Demand Conference - The Manila Times

Jul 22, 2025

Jul 22, 2025

Exclusive: Moleculin CEO Shares Vision Behind Revolutionary Cancer Drug Pipeline in New Investor Presentation - Stock Titan

Jul 22, 2025

Jul 21, 2025

Moleculin Biotech Gains Approval for Phase 2B/3 AML Study - MSN

Jul 21, 2025

Jul 21, 2025

What drives Moleculin Biotech Inc. stock priceConsistently high returns - Autocar Professional

Jul 21, 2025

Jul 20, 2025

What analysts say about Moleculin Biotech Inc. stockMassive wealth growth - jammulinksnews.com

Jul 20, 2025

Jul 18, 2025

Moleculin Biotech Appoints Adriano Treve as Strategic Advisor - The Globe and Mail

Jul 18, 2025

Jul 17, 2025

MBRX Surges 29.65% on Strategic Hire and Phase 3 Momentum – Is This the Catalyst for a Biotech Breakout? - AInvest

Jul 17, 2025

Jul 17, 2025

Moleculin appoints former Roche executive as strategic advisor - Investing.com Australia

Jul 17, 2025

Jul 17, 2025

Moleculin appoints former Roche executive as strategic advisor By Investing.com - Investing.com Canada

Jul 17, 2025

Jul 17, 2025

Moleculin Biotech, Inc. Appoints Adriano Treve as Strategic Advisor to Enhance Partnerships and Advance Clinical Trials - Nasdaq

Jul 17, 2025

Jul 17, 2025

Moleculin Engages Industry Veteran Adriano Treve to Explore Accelerated Strategic Partnerships - GlobeNewswire

Jul 17, 2025

Jul 15, 2025

What makes Moleculin Biotech Inc. stock price move sharplySmart Trading With Safety Margin - Newser

Jul 15, 2025

Jul 15, 2025

Why Moleculin Biotech Inc. stock attracts strong analyst attentionTriple Digit Return Forecasts - Newser

Jul 15, 2025

Jul 14, 2025

Moleculin Biotech Surges 19.5%—What's Fueling the Rally? - AInvest

Jul 14, 2025

Jul 11, 2025

Moleculin Biotech enters $6.5 million at-the-market equity offering agreement By Investing.com - Investing.com South Africa

Jul 11, 2025

Jul 11, 2025

Moleculin Biotech Enters New Stock Offering Agreement - TipRanks

Jul 11, 2025

Jul 11, 2025

Moleculin Biotech enters $6.5 million at-the-market equity offering agreement - Investing.com

Jul 11, 2025

Jul 10, 2025

Moleculin Acquires $2M Private Grant for Brain Tumor Trial at MD Anderson - BioTecNika

Jul 10, 2025

Jul 10, 2025

Moleculin Expands Phase 3 MIRACLE Clinical Trial into the Country of Georgia, Enrollment Update and Future Plans - GlobeNewswire

Jul 10, 2025

Jul 09, 2025

Moleculin receives Georgian approval for pivotal AML treatment trial By Investing.com - Investing.com India

Jul 09, 2025

Jul 09, 2025

Moleculin receives Georgian approval for pivotal AML treatment trial - Investing.com Australia

Jul 09, 2025

Jul 09, 2025

Moleculin Biotech Stock Soars 13.44% on Clinical Trial Expansion - AInvest

Jul 09, 2025

Jul 09, 2025

Moleculin Biotech, Inc. Secures RAMPA Approval for Phase 2B/3 MIRACLE Trial in Georgia, Expanding Clinical Recruitment Efforts - Nasdaq

Jul 09, 2025

Jul 09, 2025

MBRX gains RAMPA nod for pivotal Phase 2B/3 AnnAraC AML trial | THTX SEC FilingForm 6-K - Stock Titan

Jul 09, 2025

Jul 09, 2025

Moleculin's Phase 3 AML Treatment Trial Gains Momentum: 7 Patients Treated, 16 New Sites Coming - Stock Titan

Jul 09, 2025

Jul 03, 2025

Favourable Signals For Moleculin Biotech: Numerous Insiders Acquired Stock - simplywall.st

Jul 03, 2025

Jun 27, 2025

Moleculin Biotech (MBRX) Price Target Reduced to $13 by Roth Cap - GuruFocus

Jun 27, 2025

Jun 27, 2025

Moleculin Biotech Faces Nasdaq Delisting Warning - TipRanks

Jun 27, 2025

Jun 26, 2025

Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech. - AInvest

Jun 26, 2025

Jun 23, 2025

Moleculin Biotech Raises $5.9M in Public Offering - TipRanks

Jun 23, 2025

Jun 21, 2025

Health Care Stocks Stumble Amid Market Adjustments - Finimize

Jun 21, 2025

Jun 21, 2025

Moleculin Biotech prices 16.08M shares at 37c in public offering - Yahoo Finance

Jun 21, 2025

Jun 20, 2025

Moleculin Biotech prices $5.9M public offering; shares down about 47% - MSN

Jun 20, 2025

Jun 20, 2025

Moleculin Biotech's 50% Plunge Explained: Technical Sell-Off Dominates - AInvest

Jun 20, 2025

Jun 19, 2025

Moleculin Biotech (NASDAQ:MBRX) Given Buy Rating at HC Wainwright - Defense World

Jun 19, 2025

Jun 18, 2025

Moleculin Biotech (MBRX) Rating Reiterated with $4.00 Price Target | MBRX Stock News - GuruFocus

Jun 18, 2025

Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan - GuruFocus

Jun 18, 2025

Jun 18, 2025

Moleculin Receives Positive FDA Feedback on Pediatric Study Plan for Annamycin in Children with R/R AML - GlobeNewswire

Jun 18, 2025

Jun 18, 2025

Moleculin Participates in Virtual Investor “What This Means” Seg - GuruFocus

Jun 18, 2025